sj-docx-1-tam-10.1177_17588359231177018 – Supplemental material for Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review

Supplemental material, sj-docx-1-tam-10.1177_17588359231177018 for Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review by Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James P. Buteau, Declan G. Murphy, Brian Kelly, Lavinia Spain, Shahneen Sandhu, Arun A. Azad, Elizabeth Medhurst, Grace Kong and Michael S. Hofman in Therapeutic Advances in Medical Oncology